News

NSF Awards NOVA’s Biotechnology Program $550,000 for NOBLE Project

The NOVA Biotechnology and Leadership in Education (NOBLE) Project will be funded by the National Science Foundation with more than $550,000 over the next three years. The goal of the NOBLE Project is to revitalize and grow the biotechnology program. The NOBLE Project seeks to recruit students throughout the entire NOVA service area, particularly minorities in STEM, veterans and dual-enrollment students. The NOBLE Project will include faculty from the Alexandria and Manassas campuses.

The goal of the NOBLE Project is to train students in technical and professional skills to increase their competitiveness in the biotechnology job market. Students will gain additional key experiences by attending scientific conferences and connecting with scientific organizations. Importantly, the grant will provide funds for paid internships at local biotechnology companies. Work will begin this summer. Interested students should contact Xin Zhou at xzhou@nvcc.edu or David Fernandez at dfernandez@nvcc.edu.

The principle investigator (PI) of this project, Dr. David Fernandez, thanks Dr. Eun-Woo Chang, vice president of academic affairs and chief academic office; Dr. Xin Zhou, NOVA biotechnology program head; Dr. Maggie Emblom-Callahan, interim dean of MSTB Alexandria and Dr. Diane Mucci, Annandale Campus provost, for their guidance and vision in crafting this project.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business